13D Filing: Brady John Robert and Stony Hill Corp (STNY)

Page 7 of 9 – SEC Filing

On the filing date of this Schedule 13D, the Equinox Consulting beneficially owned, in the aggregate, 1,600,000 shares of common stock, representing approximately 2.6% of the Issuer’s outstanding shares of common stock, based on 15,247,600 shares of common stock issued and outstanding as of June 30, 2017, according to the Quarterly Report on Form 10-Q of the Issuer filed with the Securities and Exchange Commission on August 11, 2017.

As a group, the Reporting Persons beneficially own, in the aggregate, 2,000,000 shares of common stock of the Issuer. Based on a total of 15,247,600 shares of Common Stock of the Issuer outstanding as of June 20, 2017 (as stated above), the shares of common stock of the Issuer beneficially owned by the Reporting Persons as a group represent approximately 13.1% of the Issuer’s issued and outstanding shares of common stock.

(b) Mr. Brady directly owns and has sole voting power and sole dispositive power with respect to all of the shares of common stock reported in this Schedule 13D as being beneficially owned by him.

(c) Except as set forth in this Schedule 13D, none of the Reporting Persons has effected any transaction in the shares of common stock during the past sixty (60) days.

(d) Except for the Reporting Persons themselves, no person is known by any of the Reporting Persons to have the right to receive, or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock beneficially owned by Mr. Brady.

(e) Not applicable.

Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

Except with respect to an arrangement by and among each of the Reporting Persons to vote their respective shares of common stock as a group, to the knowledge of Mr. Brady, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between himself and any other person with respect to the securities of the Issuer, including, but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies or any pledge or contingency, the occurrence of which would give another person voting or investment power over the securities of the Issuer.

Item 7. MATERIAL TO BE FILED AS EXHIBITS.

Exhibit A: Agreement of Joint Filing of Schedule 13D.

7

Follow Applied Biosciences Corp.